biostudies-literatureWong CKLi Shu Fan Medical Fellowship for Internal Medicine3https://www.ebi.ac.uk/biostudies/studies/S-EPMC11734475biostudies-literatureUnknown11(1)<h4>Background</h4>Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity with these drugs, there is a notable lack of large-scale investigations with appropriate control groups. This study aimed to evaluate cardiovascular outcome among colorectal carcinoma patients treated with fluoropyrimidines.<h4>Methods</h4>A retrospective propensity score- matched cohort study was conducted in patients diagnosed with colorectal carcinoma between January 1, 1993 and December 31, 2021 at public hospitals in Hong Kong. Cardiovascular outcomes in patients prescribed fluoropyrimidines were compared with controls. Further analyses to compare 5-fluroracil anCardio-oncology (London, England)Cardiovascular safety of 5-fluorouracil and capecitabine in colorectal cancer patients: real-world evidence.PMC11734475N/AChor-Cheung Tam FWong CKHo ITse HFLeung RWFoo DCCChoo AChiu ACHLam THMa TFLau RLin MfalseCardiovascular safety of 5-fluorouracil and capecitabine in colorectal cancer patients: real-world evidence.<h4>Background</h4>Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity with these drugs, there is a notable lack of large-scale investigations with appropriate control groups. This study aimed to evaluate cardiovascular outcome among colorectal carcinoma patients treated with fluoropyrimidines.<h4>Methods</h4>A retrospective propensity score- matched cohort study was conducted in patients diagnosed with colorectal carcinoma between January 1, 1993 and December 31, 2021 at public hospitals in Hong Kong. Cardiovascular outcomes in patients prescribed fluoropyrimidines were compared with controls. Further analyses to compare 5-fluroracil an2025-01-01T00:00:00Z2025 Jan2025-04-22T04:43:38.262Z2025-04-05T21:02:56.073ZS-EPMC117344753981532910.1186/s40959-024-00294-2